Last reviewed · How we verify
Placebo to match OBE2109
This is a placebo formulation designed to match the appearance, taste, and administration characteristics of OBE2109 for blinded clinical trial purposes.
At a glance
| Generic name | Placebo to match OBE2109 |
|---|---|
| Sponsor | ObsEva SA |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo control, this product contains no active pharmaceutical ingredient and serves as the comparator arm in phase 3 trials. It is formulated to be indistinguishable from OBE2109 to maintain blinding integrity and allow for proper assessment of the active drug's efficacy and safety profile.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PHASE3)
- Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to match OBE2109 CI brief — competitive landscape report
- Placebo to match OBE2109 updates RSS · CI watch RSS
- ObsEva SA portfolio CI